• Cosmos Health posted Q2 2026 revenue of $18.99 million, up 28.8% year over year; H1 revenue rose 29.7% to $36.91 million.
• Adjusted EBITDA loss widened to $1.13 million in Q2 2026; adjusted gross profit climbed 58% year over year.
• Total liabilities fell 13.3% to $40.79 million at June 30, 2026; stockholders’ equity increased 12.2% to $20.67 million.
• Retired an $8 million senior secured convertible note on Aug. 28, 2026, eliminating further conversions; repurchased 5,112,000 shares for $1.11 million.
• Reaffirmed 2026 revenue guidance above $90 million; CEO Greg Siokas said cash burn fell more than 30% in H1 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030930PRIMZONEFULLFEED9820900) on September 03, 2026, and is solely responsible for the information contained therein.